A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection

Quantitative liquid chromatographic analysis of anthracyclines in biological fluids

“…In an attempt to overcome their toxicity or drug resistance, prodrugs and special pharmaceutical formulations have been developed. Since these changes often require a different analytical approach, the interested reader is referred to the individual methods regarding the analysis of peptide-conjugated [29][30][31] or polymer-bound [32] prodrugs and micellar [33], pegylated liposomal [33][34][35], liposomal [36,37] or embolizing [38][39][40] formulations. Here we present an overview of 35 original methods published since 1990 for the determination of doxorubicin, epirubicin, daunorubicin, idarubicin and metabolites in biological fluids.…”

Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

“…Details of the assay method have been described in detail elsewhere (Fraier et al, 1995;Vasey et al, 1999). Limits of quantification for free and bound doxorubicin were 0.38 ng ml Ð1 and 5.1 ng ml Ð1 respectively, and interday assay coefficient of variation ranged from 7.8 to 10.8% for free and 6.3 to 10.7% for bound doxorubicin.…”

Traces of phosgene in chloroform: Consequences for extraction of anthracyclines

“…Although the use of chloroform is currently under debate due to its toxicity, it still is a common solvent to extract anthracyclines from various biological matrices. It is used as eluting agent in SPE-procedures [18][19][20] as well as liquid-liquid extracting agent [21][22][23][24][25][26][27]. Unfortunately, no details were reported on the stabilization of chloroform.…”